CIK 0001130598
- Non-accelerated filer
- Smaller reporting company
Traws Pharma, Inc.
Sign in to watch- Ticker
- TRAW
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 267-759-3680
- Business address
- 12 PENNS TRAIL, NEWTOWN, PA, 18940
- Former names
- Onconova Therapeutics, Inc., ONCONOVA THERAPEUTICS INC
- 4 Open-market sale President and CEO sold 33,543 shares at an average $15.07 ($505,616)
- 4 Open-market sale President and CEO sold 60,000 shares at an average $15.05 ($903,000)
- 4 Open-market buy Director bought 57,295 shares at an average $11.92 ($682,689)
- 4 Open-market buy 10% owner bought 57,295 shares at an average $11.92 ($682,689)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Exercise or conversion Director acquired 32,036 shares (option exercise)
- 4 Open-market buy 10% owner bought 5,000 shares at an average $14.39 ($71,948)
- 4 Open-market buy Director bought 5,000 shares at an average $14.39 ($71,948)
- 4 Open-market buy Director bought 5,000 shares at $11.87 ($59,350)
- 4 Open-market buy 10% owner bought 5,000 shares at $11.87 ($59,350)
- 4 Open-market buy Director bought 5,000 shares at $12.10 ($60,500)
- 4 Open-market buy Director bought 19,700 shares at an average $11.99 ($236,265)
- 4 Open-market buy 10% owner bought 19,700 shares at an average $11.99 ($236,265)
- 4 Open-market buy President and CEO bought 1,100 shares at $12.02 ($13,222)
- 4 Open-market buy Director bought 1,400 shares at an average $12.17 ($17,038)
- 4 Exercise or conversion SVP, Finance & Corp. Develop. acquired 5,000 shares (option exercise)
- 4 Open-market buy Director bought 1,000 shares at an average $22.72 ($22,724)
Page 17 of 19 · 373 filings